- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 13, Issue 3, 2006
Current Medicinal Chemistry - Volume 13, Issue 3, 2006
Volume 13, Issue 3, 2006
-
-
Agonists and Antagonists of Protease Activated Receptors (PARs)
Authors: Grant D. Barry, Giang T. Le and David P. FairlieProtease activated receptors (PARs) are a category of G-protein coupled receptors (GPCRs) implicated in the progression of a wide range of diseases, including thrombosis, inflammatory disorders, and proliferative diseases. Signal transduction via PARs proceeds via an unusual activation mechanism. Instead of being activated through direct interaction with an extracellular signal like most GPCRs, they are self-activated foll Read More
-
-
-
Urotensin-II Receptor Antagonists
Authors: A. Carotenuto, P. Grieco, P. Rovero and E. NovellinoUrotensin-II (U-II) is a "somatostatin-like" cyclic neuropeptide which was originally isolated from goby fish urophysis, and subsequently identified in other species, including man. The interest in human U-II (hU-II) has grown enormously in the last few years, following the identification of a specific human receptor (formerly identified as the GPR14/SENR orphan receptor), now referred to as UT receptor. The U-II/UT system seems to Read More
-
-
-
Prediction Oriented QSAR Modelling of EGFR Inhibition
Authors: C. Szantai-Kis, I. Kovesdi, D. Eros, P. Banhegyi, A. Ullrich, G. Keri and L. OrfiEpidermal Growth Factor Receptor (EGFR) is a high priority target in anticancer drug research. Thousands of very effective EGFR inhibitors have been developed in the last decade. The known inhibitors are originated from a very diverse chemical space but - without exception - all of them act at the Adenosine TriPhosphate (ATP) binding site of the enzyme. We have collected all of the diverse inhibitor structures and the relevant Read More
-
-
-
P2 Receptors Activated by Uracil Nucleotides - An Update
Authors: Andreas Brunschweiger and Christa E. MullerPyrimidine nucleotides, including UTP, UDP and UDP-glucose, are important signaling molecules which activate G protein-coupled membrane receptors (GPCRs) of the P2Y family. Four distinct pyrimidine nucleotidesensitive P2Y receptor subtypes have been cloned, P2Y2, P2Y4, P2Y6 and P2Y14. P2Y2 and P2Y4 receptors are activated by UTP (the P2Y2, and the rat but not the human P2Y4 receptor are also activated by AT Read More
-
-
-
HIV-1 Reverse Transcriptase: A Therapeutical Target in the Spotlight
Human Immunodeficiency Virus type 1 Reverse Transcriptase (HIV-1 RT) is one of the most important targets for treatment of Acquired Immune Deficiency Syndrome (AIDS). It catalyzes the reverse transcription of HIV-RNA into a double stranded DNA, and the knowledge of its substrate specificity and catalytic mechanism has guided the development of several inhibitors widely used on current HIV/AIDS therapy. However, Read More
-
-
-
Taking Advantage of Viral Immune Evasion: Virus-Derived Proteins Represent Novel Biopharmaceuticals
Authors: L. Amati, M. E. Passeri, A. Lippolis, D. Lio, C. Caruso, E. Jirillo and V. CovelliIn healthy individuals, natural and adaptive immune responses are able to control virus entry into the host. In particular, CD8+-mediated cytotoxicity, sustained by the intervention of CD4+ cells, represents the major key event leading to virus eradication. On the other hand, viruses are able to evade from host immune response via several mechanisms, and special emphasis will be placed on hepatitis C virus and chronic Read More
-
-
-
Progresses in the Field of Drug Design to Combat Tropical Protozoan Parasitic Diseases
Authors: Guadalupe E. G. Linares, Esteban L. Ravaschino and Juan B. RodriguezThe progresses made in the field of drug design to combat tropical protozoan parasitic diseases, such as Chagas' disease, leishmaniasis, and sleeping sickness are discussed. This article is focused on different approaches based on unique aspects of parasites biochemistry and physiology, selecting the more promising molecular targets for drug design. In spite of the enormous amount of work on the above features, the ch Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
